Form 4: Kalaris Therapeutics Director Receives Stock Option Grant

Director Morana Jovan-Embiricos was granted 9,000 stock options in Kalaris Therapeutics, Inc. with an exercise price of $4.72.

Summary

• Director Morana Jovan-Embiricos received a grant of 9,000 stock options on June 3, 2026.
• The options have an exercise price of $4.72 per share.
• The options are scheduled to vest in full on the earlier of June 3, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Continued service requirement for the vesting of the granted options.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant of stock options to non-executive directors is consistent with standard compensation packages for small-cap biotechnology firms.
• The one-year cliff vesting schedule is a common practice for director equity awards.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 3, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Kalaris Therapeutics, KLRS, Form 4, Insider Trading, Stock Options, Director Compensation